A Parental Request for an Unproven Treatment for a Rare Pediatric Cancer: Sound Reasons for Not Going Off-Label
Abstract
We present the case of a three-year-old in remission from ependymoma whose parents requested off-label metformin in the hope that it could reduce her chance of recurrence. A prominent specialist who was developing a clinical trial studying metformin as an adjunctive treatment for children with relapsed ependymoma had recommended metformin for the patient based on theoretical chance of benefit. The child's primary neuro-oncologist sought an ethics consult, as he did not believe that prescribing metformin off-label to this patient was ethical. We argue that he should not prescribe the medication. Current data do not support its use, and it carries nontrivial risks. Moreover, prescribing unproven treatments outside of a trial risks giving families false hope, undermining clinical research, and creating pressure on physicians to offer unproven interventions. Social media amplifies these requests, shaping parental decision-making and potentially spreading unvalidated practices. Physicians may respond compassionately while declining to provide interventions outside standard care. This case highlights the ethical boundaries of off-label prescribing in pediatric oncology.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.